...
【24h】

Acute severe hypothyroidism induced by sunitinib

机译:舒尼替尼引起的急性严重甲状腺功能减退

获取原文
获取原文并翻译 | 示例
           

摘要

Sunitinib (Sutent, Pfizer Inc., La Jolla, CA) is an orally bioavailable small-molecule tyrosine kinase inhibitor for vascular endothelial growth factor receptors 1 and 2 (VEG-FR1 and VEGFR2), platelet-derived growth factor receptors alpha and beta (PDGFRa and PDGFRp), glial cell-line derived neurotrophic factor receptor (RET), stem cell factor receptor (KIT), and FMS-like tyrosine kinase 3 (FLT-3) approved for the treatment of imatinib-refractory gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma. Although the drug is well tolerated, common toxic effects of sunitinib include fatigue (34%), diarrhea (33%), skin discoloration (25%), nausea (24%), and anorexia (19%), usually of mild to moderate intensity . Among them, fatigue might be, at least partially, secondary to the onset of sunitinib-induced hypothyroidism [2-6]. We report here a case of severe hypothyroidism associated with sunitinib after 2 weeks of treatment for advanced GIST.
机译:Sunitinib(Sutent,Pfizer Inc.,La Jolla,CA)是口服生物利用的小分子酪氨酸激酶抑制剂,用于血管内皮生长因子受体1和2(VEG-FR1和VEGFR2),血小板衍生的生长因子受体α和β( PDGFRa和PDGFRp),神经胶质细胞源性神经营养因子受体(RET),干细胞因子受体(KIT)和FMS样酪氨酸激酶3(FLT-3)被批准用于治疗伊马替尼难治性胃肠道间质瘤(GIST) )和晚期肾细胞癌。尽管药物耐受性良好,但舒尼替尼的常见毒性作用包括疲劳(34%),腹泻(33%),皮肤变色(25%),恶心(24%)和厌食症(19%),通常为轻度至中度强度。其中,疲劳可能至少部分是继舒尼替尼引起的甲状腺功能减退症发作后继发的[2-6]。我们在这里报告了晚期GIST治疗2周后与舒尼替尼相关的严重甲状腺功能减退的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号